Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy-Reference-Cited by-同舟云学术

Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy

Published:2024-02-13 Issue:3 Volume:484 Page:465-473
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Kaimi Yuto,Takahashi Yuka,Taniguchi Hirokazu,Ochi Tetsuro,Makino Haruhi,Makita Shinichi,Iwaki Noriko,Fukuhara Suguru,Munakata Wataru,Ogawa Chitose,Izutsu Koji,Maeshima Akiko Miyagi^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00428-024-03764-1.pdf

Reference17 articles.

1. van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM (2017) Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. https://doi.org/10.1038/bcj.2017.85

2. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC (2010) Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 16:888–897. https://doi.org/10.1158/1078-0432.CCR-09-2069

3. Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK (2019) Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol 46:823–829. https://doi.org/10.1111/cup.13545

4. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP (2016) Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol 43:1161–1166. https://doi.org/10.1111/cup.12797

5. Arai H, Furuichi S, Nakamura Y, Nakamura Y, Ichikawa M, Mitani K (2016) ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. Rinsho Ketsueki 57:634–637. Japanese. https://doi.org/10.11406/rinketsu.57.634

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers;Molecular Therapy: Oncology;2024-09